BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA

뉴스 본문을 불러오고 있어요.

BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA | 웨이프 WAPE

BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA

기사 요약

관련 종목

댓글 —